Choices of anticoagulation therapies are not simple as it was before, it does not mean that it was safer before. The new guideline from CHEST gave Level 2B recommendations to the new generation of NOVACs. Dabigatran (Grade 2B), Rivaroxaban (Grade 2B), Apixaban (Grade 2B), or Edoxaban (Grade 2B) was reviewed.